Article metrics

Download PDFPDF

800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to May 2021

AbstractFullPdf
Nov 2020176012
Dec 20207604
Jan 20212805
Feb 20212004
Mar 20212208
Apr 20217409
May 20212008
Total416050